Cargando…
New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments
Clear cell Renal Cell (RCC) and Head and Neck Squamous Cell Carcinomas (HNSCC) are characterized by a pro-angiogenic/pro-inflammatory context. Despite conventional or targeted therapies, metastatic RCC and HNSCC remain incurable. Alternative treatments to reference therapies (sunitinib, a multi tyro...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691587/ https://www.ncbi.nlm.nih.gov/pubmed/31410218 http://dx.doi.org/10.7150/thno.34681 |
_version_ | 1783443408897966080 |
---|---|
author | Dufies, Maeva Grytsai, Oleksandr Ronco, Cyril Camara, Oumar Ambrosetti, Damien Hagege, Anaïs Parola, Julien Mateo, Lou Ayrault, Marion Giuliano, Sandy Grépin, Renaud Lagarde, Nathalie Montes, Matthieu Auberger, Patrick Demange, Luc Benhida, Rachid Pagès, Gilles |
author_facet | Dufies, Maeva Grytsai, Oleksandr Ronco, Cyril Camara, Oumar Ambrosetti, Damien Hagege, Anaïs Parola, Julien Mateo, Lou Ayrault, Marion Giuliano, Sandy Grépin, Renaud Lagarde, Nathalie Montes, Matthieu Auberger, Patrick Demange, Luc Benhida, Rachid Pagès, Gilles |
author_sort | Dufies, Maeva |
collection | PubMed |
description | Clear cell Renal Cell (RCC) and Head and Neck Squamous Cell Carcinomas (HNSCC) are characterized by a pro-angiogenic/pro-inflammatory context. Despite conventional or targeted therapies, metastatic RCC and HNSCC remain incurable. Alternative treatments to reference therapies (sunitinib, a multi tyrosine kinase inhibitor for RCC or cisplatin for HNSCC) are urgently needed on relapse. Here, we described the relevance of targeting the ELR+CXCL cytokines receptors, CXCR1/2, for the treatment of these two cancer types. Methods: The relevance to patient treatment was evaluated by correlating the ELR(+)CXCL/CXCR1/2 levels to survival using online available data. We report herein the synthesis of new pharmacological inhibitors of CXCR1/2 with anti-proliferation/survival activity. The latter was evaluated with the XTT assay with leukemic, breast, RCC and HNSCC cell lines. Their relevance as an alternative treatment was tested on sunitinib- and cisplatin- resistant cells. The most efficient compound was then tested in a mouse model of RCC and HNSCC. Results: RCC and HNSCC expressed the highest amounts of CXCR1/2 of all cancers. High levels of ELR(+)CXCL cytokines (CXCL1, 2, 3, 5, 6, 7, 8) correlated to shorter survival. Among the 33 synthesized and tested molecules, compound C29 reduced ELR(+)CXCL/CXCR1/2-dependent proliferation and migration of endothelial cells. C29 exerted an anti-proliferation/survival activity on a panel of cancer cells including naive and resistant RCC and HNSCC cells. C29 reduced the growth of experimental RCC and HNSCC tumors by decreasing tumor cell proliferation, angiogenesis and ELR(+)/CXCL-mediated inflammation. Conclusion: Our study highlights the relevance of new CXCR1/2 inhibitors for the treatment of RCC or HNSCC as first-line treatment or at relapse on reference therapies. |
format | Online Article Text |
id | pubmed-6691587 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-66915872019-08-13 New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments Dufies, Maeva Grytsai, Oleksandr Ronco, Cyril Camara, Oumar Ambrosetti, Damien Hagege, Anaïs Parola, Julien Mateo, Lou Ayrault, Marion Giuliano, Sandy Grépin, Renaud Lagarde, Nathalie Montes, Matthieu Auberger, Patrick Demange, Luc Benhida, Rachid Pagès, Gilles Theranostics Review Clear cell Renal Cell (RCC) and Head and Neck Squamous Cell Carcinomas (HNSCC) are characterized by a pro-angiogenic/pro-inflammatory context. Despite conventional or targeted therapies, metastatic RCC and HNSCC remain incurable. Alternative treatments to reference therapies (sunitinib, a multi tyrosine kinase inhibitor for RCC or cisplatin for HNSCC) are urgently needed on relapse. Here, we described the relevance of targeting the ELR+CXCL cytokines receptors, CXCR1/2, for the treatment of these two cancer types. Methods: The relevance to patient treatment was evaluated by correlating the ELR(+)CXCL/CXCR1/2 levels to survival using online available data. We report herein the synthesis of new pharmacological inhibitors of CXCR1/2 with anti-proliferation/survival activity. The latter was evaluated with the XTT assay with leukemic, breast, RCC and HNSCC cell lines. Their relevance as an alternative treatment was tested on sunitinib- and cisplatin- resistant cells. The most efficient compound was then tested in a mouse model of RCC and HNSCC. Results: RCC and HNSCC expressed the highest amounts of CXCR1/2 of all cancers. High levels of ELR(+)CXCL cytokines (CXCL1, 2, 3, 5, 6, 7, 8) correlated to shorter survival. Among the 33 synthesized and tested molecules, compound C29 reduced ELR(+)CXCL/CXCR1/2-dependent proliferation and migration of endothelial cells. C29 exerted an anti-proliferation/survival activity on a panel of cancer cells including naive and resistant RCC and HNSCC cells. C29 reduced the growth of experimental RCC and HNSCC tumors by decreasing tumor cell proliferation, angiogenesis and ELR(+)/CXCL-mediated inflammation. Conclusion: Our study highlights the relevance of new CXCR1/2 inhibitors for the treatment of RCC or HNSCC as first-line treatment or at relapse on reference therapies. Ivyspring International Publisher 2019-07-09 /pmc/articles/PMC6691587/ /pubmed/31410218 http://dx.doi.org/10.7150/thno.34681 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Dufies, Maeva Grytsai, Oleksandr Ronco, Cyril Camara, Oumar Ambrosetti, Damien Hagege, Anaïs Parola, Julien Mateo, Lou Ayrault, Marion Giuliano, Sandy Grépin, Renaud Lagarde, Nathalie Montes, Matthieu Auberger, Patrick Demange, Luc Benhida, Rachid Pagès, Gilles New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments |
title | New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments |
title_full | New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments |
title_fullStr | New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments |
title_full_unstemmed | New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments |
title_short | New CXCR1/CXCR2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments |
title_sort | new cxcr1/cxcr2 inhibitors represent an effective treatment for kidney or head and neck cancers sensitive or refractory to reference treatments |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691587/ https://www.ncbi.nlm.nih.gov/pubmed/31410218 http://dx.doi.org/10.7150/thno.34681 |
work_keys_str_mv | AT dufiesmaeva newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT grytsaioleksandr newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT roncocyril newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT camaraoumar newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT ambrosettidamien newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT hagegeanais newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT parolajulien newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT mateolou newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT ayraultmarion newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT giulianosandy newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT grepinrenaud newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT lagardenathalie newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT montesmatthieu newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT aubergerpatrick newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT demangeluc newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT benhidarachid newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments AT pagesgilles newcxcr1cxcr2inhibitorsrepresentaneffectivetreatmentforkidneyorheadandneckcancerssensitiveorrefractorytoreferencetreatments |